Hypothesis

Repeated low‑dose (sub‑perceptual) psilocybin administration will produce a measurable increase in synaptic density and fear‑extinction retention only when each dose is paired with a brief, controlled reactivation of the trauma memory. In the absence of memory reactivation, the same microdosing regimen will not alter synaptic biomarkers or clinical PTSD symptoms beyond placebo.

Rationale

• Full‑dose psilocybin acutely activates 5‑HT2A receptors, triggering a cascade that includes ERK/MAPK phosphorylation, mTORC1 signaling, and BDNF release, which together drive rapid synaptogenesis (2).
• Preclinical work shows that a single full dose rescues fear extinction in mice by boosting hippocampal neurogenesis and dendritic growth (1).
• However, the antidepressant effect of psilocybin appears blunted by prior chronic SSRI exposure, suggesting that baseline serotonergic tone modulates plasticity outcomes (3).
• Microdosing produces plasma concentrations insufficient to cause hallucinations but sufficient to engage 5‑HT2A receptors at a level that can still initiate downstream signaling without overwhelming network noise.
• Synaptic tagging and capture theory posits that plasticity‑related proteins synthesized during a labile window are captured at recently activated synapses, stabilizing long‑term changes (5). Applying this to fear memory, a brief memory reactivation creates a synaptic tag; subsequent psilocybin‑induced mTOR‑dependent protein synthesis would then be captured, strengthening extinction traces.

Testable Predictions

1. Biomarker level – Participants receiving microdosin + memory reactivation will show a ≥4% increase in cortical SV2A PET signal after 4 weeks, whereas microdose‑only and placebo groups will show <1% change (null effect).
2. Behavioral level – Clinician‑administered CAPS‑5 scores will improve by ≥12 points in the combined group, exceeding the minimal clinically important difference, while microdose‑only and placebo groups will change ≤4 points.
3. Neurophysiological level – Resting‑state fMRI will reveal increased fronto‑amygdala connectivity specifically in the combined group, correlating with SV2A changes (r > 0.4).
4. Specificity – The effect will disappear if the memory reactivation is omitted or replaced with a neutral task, confirming the dependence on memory‑dependent tagging.

Experimental Design (Outline)

• Population: 80 adults with DSM‑5 PTSD (CAPS‑5 ≥ 30), stratified by current SSRI use (yes/no).
• Groups (2×2 factorial): microdose (1 mg psilocybin every 3 days) vs placebo; memory reactivation (5‑min guided trauma recall) vs neutral task (watching nature video).
• Duration: 4 weeks dosing + weekly reactivation sessions.
• Outcomes: baseline and week‑4 SV2A PET, hippocampal volumetric MRI, fear‑potentiated startle, CAPS‑5, and MADRS.
• Analysis: Mixed‑effects models testing interaction between drug and reactivation on each outcome; pre‑registered falsifiability criteria as above.

Mechanistic Insight

The hypothesis extends the observed macrodose effects by proposing that temporal contiguity between a plasticity‑permissive biochemical state (low‑dose psilocybin‑driven mTOR activation) and a neuronal tag (reactivated fear engram) is required for lasting synaptic remodeling. This explains why open‑label macrodose studies show benefit without explicit psychotherapy (the drug’s intense experience may itself serve as a salient tag), while microdosing alone may be subthreshold for tag formation. Demonstrating an interaction would not only validate microdosing as a viable PTSD tool but also refine dosing strategies to maximize neuroplasticity while minimizing acute psychedelic exposure.

If the interaction fails to materialize, the hypothesis is falsified, suggesting that either sub‑perceptual dosing does not engage mTOR sufficiently or that memory tagging is not the limiting factor for microdose‑induced plasticity in humans.